热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　映恩生物-B（09606）公布配发结果，香港公开发售的发售股份数目（经重新分配后调整）为753.58万股，国际发售的发售股份数目（经计及发售量调整权获悉数行使及经重新分配后调整）为979.65万股。最终发售价为每股94.6港元，全球发售净筹约15.13亿港元。每手100股，预期股份将于2025年4月15日（星期二）开始在联交所买卖。

　　其中，香港公开发售获115.14倍认购，国际配售获13.52倍认购。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.